Daewoong
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Daewoong is a holding company listed on KOSPI, Korea's main stock exchange, that sits above a group of health-care subsidiaries engaged in pharmaceuticals, biotech, and related businesses.
Its operating revenue at the parent level consists of service fees, royalties, and dividends received from those subsidiaries. The single most important structural fact is that Daewoong itself does not directly make or distribute medicines, it earns income by managing and providing services to its subsidiary network, with key operating businesses including a pharmaceutical subsidiary and a biotech subsidiary.
Summary is AI-generated and may contain errors · figures from DART filings
Daewoong is a holding company whose main operating subsidiaries include Daewoong Pharmaceutical and Daewoong Bio, each separately run but consolidated under the parent.
Daewoong in five facts
What does Daewoong do?
Daewoong is a holding company listed on KOSPI, Korea's main stock exchange, that sits above a group of health-care subsidiaries engaged in pharmaceuticals, biotech, and related businesses.
Where is Daewoong listed and in which sector?
Daewoong (Korean name: 대웅) trades under KRX code 003090 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Daewoong?
Its market capitalisation was US$665.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Daewoong's latest annual revenue and operating profit?
For fiscal year 2025, Daewoong reported revenue of US$1.6B, operating profit of US$197.6M and net income of US$172M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 6.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Decision to guarantee a third party's debt (subsidiary)Sep 4
- DisclosureSep 2
- Supply contract signed (subsidiary)
Daewoong disclosed a subsidiary's supply contract with Acino Pharma AG, worth US$59.9M, about 5.89% of the subsidiary's recent annual revenue, running through Jun 2036.
Supply contract · Jun 26 - Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
Daewoong reported a subsidiary's separate results for FY2025: revenue of US$7.64M (+22.8% year on year), an operating loss of US$160K and net income of US$1.1M (+121.7% year on year).
Earnings · Mar 9 - Cash/in-kind dividend decision (subsidiary)Dividend · Feb 25
- Cash/in-kind dividend decision
Daewoong declared a cash dividend of US$0.14 per share.
Dividend · Feb 25 - Supply contract terminated (subsidiary)Supply contract · Feb 12
- Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
Daewoong reported a subsidiary's consolidated results for FY2025: revenue of US$1.07B (+10.4% year on year), operating profit of US$135M (+33% year on year) and net income of US$131M (+721.1% year on year).
Earnings · Feb 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Daewoong reported consolidated results for FY2025: revenue of US$1.41B (+6.8% year on year), operating profit of US$179M (−7% year on year) and net income of US$152M (+222.9% year on year).
Earnings · Feb 9 - Material event report (treasury share disposal)Treasury Shares · Jan 12